The anticancer drug bicalutamide, clinically used in prostate cancer patients, has been shown to enhance SPTAN1-mediated apoptosis by calpain or caspase 3 leading to cell shrinkage and membrane blebbing [76]. Here, SPTAN1 is linked to prostate cancer.